MBD4 acts as safeguard against damage from 5mC deamination and its deficiency results in increased risk to develop CHIP/AML, colorectal polyposis and uveal melanoma with significantly increased mutational burden compared to sporadic cases (35, 36). This evidence concerns the gene MBD4 and acute myeloid leukemia.